Pharmaceutical
ChemLinkedChemicalFoodCosmeticPharmaceuticalJapanAgrochemicalSustainability
News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
INDUSTRY
Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Cancer Cardiovascular Disease Rare Disease Drug Registration New Drug
Monthly Report: New Drug Approvals in China | March 2022 In March 2022, China NMPA approved 23 new drugs, including 15 chemical drugs and 8 biological products.
Apr 07, 2022
INDUSTRY
Innovative Drug Generic Drug Biosimilar New Drug COVID-19
Multinational Pharma Companies Record Sales Growth in 2021 Johnson & Johnson ranks the first with global sales of 93.77 billion USD. Pfizer has the most rapid growth in global sales, zooming up by 95% to 81.3 billion USD. AstraZeneca is the largest foreign pharma company regarding its 5.99 billion USD sales in China. MSD records the most vigorous sales growth in China of 60%, bringing the sales to 4.26 billion USD.
Mar 18, 2022
INDUSTRY
Marketing Approval COVID-19
China Approves Eleven COVID-19 Antigen Self-test Kits China has approved eleven COVID-19 antigen self-test kits to enhance its early detection amid the recent rise of COVID-19 confirmed cases and asymptomatic infections.
Mar 16, 2022
INDUSTRY
Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Cancer Drug Registration New Drug COVID-19
Monthly Report: New Drug Approvals in China | February 2022 In February 2022, China NMPA approved 16 new drugs, including 12 chemical drugs and 4 biological products. Among the newly approved drugs, Pfizer’s Paxlovid is the first foreign drug against COVID-19 to receive marketing authorization in China.
Mar 11, 2022
INDUSTRY
Marketing Approval Innovative Drug Drug Registration New Drug COVID-19
China Approves Pfizer's Paxlovid, Encouraging COVID-19 Drug Development On Feb. 11, China NMPA conditionally granted the emergency approval to Pfizer's co-packaged nirmatrelvir tablets and ritonavir tablets (Paxlovid).
Feb 28, 2022
INDUSTRY
Marketing Approval Innovative Drug Generic Drug Biological Product Biosimilar New Drug
Monthly Report: New Drug Approvals in China | January 2022 In January 2022, China NMPA approved 15 new drugs, including 10 chemical drugs and 5 biological products.
Feb 17, 2022
INDUSTRY
Priority Review NRDL Rare Disease
Biogen's Drug for Rare Disease SMA Gets Access to More Patients in China Due to NRDL In December 2021, Biogen cut the price of Spinraza (Nusinersen Sodium Injection) from 700,000 yuan per dose to 33,000 yuan per dose to get a place in China’s National Reimbursement Drug List (NRDL). The move makes Spinraza gain access to more spinal muscular atrophy (SMA) patients in China.
Feb 14, 2022
INDUSTRY
NRDL Health Insurance
Best-selling Ophthalmic Drugs in China | Market Wrap 2021 The year 2021 has seen a remarkable growth of the ophthalmic drug market in China. The market size of chemical drugs for eye diseases is estimated to exceed 3.5 billion yuan (circa 549 million USD), with a year-on-year growth of 1.89%.
Jan 10, 2022
INDUSTRY
Marketing Approval Drug Registration New Drug
Monthly Report: New Drug Approvals in China | Dec 2021 In Dec 2021, China NMPA approved 11 new drugs, including 7 chemical drugs and 4 biological products.
Jan 07, 2022
INDUSTRY
Marketing Approval Innovative Drug Biological Product Cancer Drug Registration New Drug
Monthly Report: New Drug Approvals in China | Nov. 2021 In Nov. 2021, China's NMPA approved seven new drugs, including three chemical drugs and four biological products.
Dec 15, 2021
Pre 1... 56789 Next
Most Popular